Mind Matters: How To Deal And Cope With Grief – CNBCTV18

In this latest episode of the special series Mind Matters: An invitation to wellbeing, the endeavour is to encourage more people to come forward and seek help when needed.

This episode will focus on the complexities of grief. Grief is a natural response to loss, the emotional suffering you feel when something or someone you love is taken away. This loss can be of any kind, the loss of a loved one, the loss of a job, the loss of a relationship, or even a subtle loss.

Grief or the pain caused by this loss can be overwhelming and can also disrupt physical health making it difficult to eat, sleep or think straight. Grief is both universal and a personal experience. Yet there is often a timeline given to grieving and this can often mean that it goes unresolved.

There is no correct way to grieve and yet because of certain pressures that society puts many leave it unacknowledged and this then becomes a cause for other mental illnesses. In an effort to understand grief better, CNBC-TV18 spoke to Dr Shyam Bhat, Psychiatrist, Integrative Medicine Specialist, and Chairperson of LiveLoveLaugh Foundation; and Urmila Kandha, a fintech specialist sharing her experience, her story of grief and also of hope.

Watch video for more

First Published:Apr 21, 2022, 07:59 PM IST

Read this article:
Mind Matters: How To Deal And Cope With Grief - CNBCTV18

Debate continues over CBD therapy – DVM 360

A lot has happened since 2018 when published results of the first clinically relevant peer-reviewed study showed safety and efficacy of cannabidiol (CBD) in reducing pain in dogs with osteoarthritis.1

Despite being used for thousands of years in both humans and animals, cannabinoidsthe therapeutic molecules found in Cannabis sativa Linnaeushave been stigmatized or considered an illegitimate or illegal therapeutic tool for veterinary patients since the 1930s. This largely stemmed from legal prohibition at the federal level, which still exists today.2 There is much to be done to educate clinicians about the therapeutic indications for cannabinoids, as well as dosing ranges and harm reduction.

For clinical application, data from preclinical studies and veterinary specific clinical trials show the legitimacy and usefulness of these compounds in veterinary populations. This is especially true when comparing cannabinoid use with other novel or integrative techniques already well adopted by veterinary practitioners despite limited or conflicting evidence. However, the data on how these compounds work still need further research and dissemination to practitioners, in addition to larger powered studies and diversity in clinical use.

RESEARCH UPDATES

Although there is no FDA-approved veterinary CBD product currently available, at least 10 pharmacokinetic (PK) studies on CBD in dogs have been published, in addition to 3 safety studies evaluating clinical presentation of CBD-dominant products at various doses.1,3-12 For cats, there are 2 PK studies and 2 safety studies at variousdoses.12,13

In addition, there have been 2 published PK studies on horses, and 1 PK study on dairy calves, and multiple PK studies are underway on various species.14-19 It should be noted, given the vastly different formulations and ratios of various cannabinoids (there are more than 120 described so far), that it cannot be assumed all products will have the same bioavailability or efficacy when compared with those used in the published studies. Despite alkaline phosphatase elevations in a small percentage of dogs and a transient alanine aminotransferase elevation in 1 cat in 1 of the studies, the therapeutic index appears to be very high, meaning these products are safe when properly manufactured and tested.

Studies on pain management with cannabinoids such as CBD have not addressed effectiveness on acute pain, although anecdotes suggest effectiveness. However, 5peer-reviewed studies show moderate to good efficacy in decreasing pain scores in dogs with chronic pain from osteoarthritis.1,20-23 Another possible use of cannabinoids is for epilepsy. One published study showed an approximate 33% decrease in seizure frequency and severity with the addition of what is considered a low dose of aCBD-dominant product for dogs with intractable idiopathic epilepsy when comparing dosing of CBD for epilepsy in people.24 A longer-term study using a higher dose isunderway.

Results of a randomized PK study showed that administering phenobarbital with a CBD product led to no major concerns for drug-to-drug interaction.25 In addition, anxiety and behavior modification warrant better-designed clinical studies. Two published studies show some or no change in the temperament of shelter dogs given CBD when exposed to loud auditory triggers and animal caretakers.26,27 Other studies are investigating CBD use for conditions such as atopic dermatitis in dogs, stomatitis in cats, epilepsy in dogs, quality of life in canine patients with cancer, acute pain in dogs, and anxiety in cats.

LEGISLATIVE UPDATES

Products derived from hempdefined as any cannabis plant with less than 0.3% -9-tetrahydrocannabinol (THC)remain legal at the federal level, whereas the legality of products derived from marijuana (defined as any cannabis plant with more than 0.3% THC) varies from state to state. Even in states where all forms and uses of cannabis have been decriminalized, guidance from state boards of veterinary medicine ranges from no guidance to legislation and regulations around veterinarians ability to recommend or even discuss the use of cannabis in their patients. In Nebraska and Idaho, any cannabis-derived product is illegal, regardless of whether it comes from marijuana or hemp.

The authors reached out to 48states veterinary medicine boards and received responses from 19 (Table28-33). The authors believe that products derived from hemp belong in the same category as other nutraceuticals or supplements that veterinarians recommend every day, often with less scientific backing and data than what exists for cannabinoid-containing products. To that end, CBD has a monograph in Plumbs Veterinary Drug Handbook.34

EMERGING PRODUCT TRENDS

Cannabigerol (CBG)

Research on this cannabinoid is limited but growing.35 CBG is a precursor molecule for many of the cannabinoids produced by the cannabis plant, including both CBD and TCH. It is noninebriating and demonstrates effects on the neurological system, making it a potential therapeutic in epilepsy and other neurological conditions. Human studies are underway for its use in Huntington disease, Parkinson disease, irritable bowel syndrome, and inflammatory bowel disease. Ithas high affinity for both 2 and serotoninreceptors.

Cannabinol (CBN)

This cannabinoid is a product of oxidation or aging of THC and is often found in products that have been stored for long periods or those exposed to heat during storage. It binds to CB1 receptors in the endocannabinoid system, just as THC does, but is approximately 75%less potent at these receptors than THC. In historic studies, CBN has shown sedative and anticonvulsant effects, which has led to its use as a sleep aid in humans. Recent human-based research has not demonstrated clear evidence of CBN as a sleep aid, though it may work in this way as part of the entourage effect when combined with other cannabinoids and terpenes in full- and broad-spectrum products.36

Nepetalactone This terpene has been isolated as the primary active ingredient in catnip and silvervine and is 1 of the hundreds of terpenes found in cannabis. At least 1 veterinary cannabis company is looking to develop nepetalactone in feline products to harness its therapeutic effects of mild sedation andeuphoria.

-8 THC

The new kid on the block, -8 THC is a molecule that can be synthesized from CBD, including CBD that is derived from hemp. In this way, it is marketed as legal THC. It is completely unregulated and requires the heavy use of industrial solvents and other chemicals to force the conversion of CBD to -8 THC, some of which may remain in any final product. ProVerde Laboratories has tested hundreds of such products with a wide variation in cannabinoids and other molecules found, some of which have no safety data whatsoever. -8 THC is reported to be anywhere from 20% to 80% less potent than -9 THC (the naturally occurring isomer of THC found in cannabis), requiring much higher doses for similar effects. There is no veterinary indication for its use, and safety concerns, as well as lack of consistency, make it questionable for human use as well.37

For information on the legal status of all forms of cannabis in your state, visit https://www.norml.org/laws/

Liz Hughston, MEd, RVT, CVT, LVT, LMVT, VTS (SAIM) (ECC); and Stephen Cital, RVT, SRA, RLAT, CVPP, VTS-LAM, co-authored the textbook Cannabis Therapy in Veterinary Medicine: A Complete Guide, with fellow co-authors Katherine Kramer and James S. Gaynor. The book was released in 2021.

References

Read more:
Debate continues over CBD therapy - DVM 360

Ear Seeds: What Is Ear Seeding and How Does It Work? Experts Explain – Good Housekeeping

They look great in a pair of earrings, but chances are, you don't pay too much attention to your ears on a day-to-day basis. Yet social media influencers keeping up on the latest wellness trends have been seemingly obsessed with their ridged cartilage and lobes thanks to ear seeding, a modern take on acupressure that targets well-established acupuncture points within our ears.

In traditional Chinese medicine, the ear is considered a microsystem: A representation of the whole body. The ear looks like an upside-down baby with the lobe being the head, the interior ridge being the spine, and the internal organs along with the recessed areas, explains Tom Ingegno, a doctor of acupuncture and Chinese medicine based in Baltimore, Maryland.

Thats why, he explains, when pressure is applied to different spots of the ear in the ear seeding process, otherwise known as auriculotherapy, it can stimulate that point of the body. And when it does, it can help you in all sorts of ways by easing pain, lessening stress, easing allergies and more.

Ear seeds are, essentially, what they sound like: little seeds.

In traditional Chinese medicine, they are seeds of the Vaccaria plant, a type of seed that is roughly the size of poppy seeds. This [vaccaria plant] herb is used for its blood moving properties and also reduces swelling, relieves pain and promotes healing, says Sandra Subotich, a doctor of acupuncture and director of eastern medicine at Chicago-based Bian.

Today, ear seeds arent just seeds anymore. Some acupuncturists and stores sell some made of steel, silver, gold, crystal or magnets. Regardless of what theyre made of, the seeds are applied to different acupuncture spots of your ear using an adhesive or waterproof tape.

Once applied, you can wear the seeds all day or up to three to five days tops, if the adhesive holds.

Ear seeds are used to stimulate acupuncture points in the ear, by providing a constant stimulation, Subotich explains. Since the ear is a Microsystem of the entire body, ear seeds can be used to address a wide variety of issues.

These issues, according to Subotich, include sleep problems, stress and anxiety, depression, headaches, addiction, weight management and holistic pain management. Research on substantiated benefits associated with ear seeding is limited, but many practitioners convey these potential benefits to those interested in exploring naturopathic treatment options.

Ear seeding has enjoyed a boom in popularity during the pandemic. During these stressful times, ear seeding has included treating healthcare workers who are overworked and exhausted, explains Barbara Gosse, an acupuncturist and educator with Northwestern Health Sciences University, because they may help ease insomnia side effects, and help individuals deal with stress and anxiety.

Pressing on the seeds helps to more intensely stimulate the point and thereby stimulate the underlying nerves, Subotich says. This sends a stronger message through the neural pathways and helps to modulate the desired effect.

This content is imported from Instagram. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

In many ways, ear seeding is similar to acupuncture but it doesnt require any needles, which is an advantage to anyone thats got a bit of trypanophobia. Ear seeds are also easier to administer, which means that once you know where to put them, you can apply them yourself.

Ear seeds also only apply pressure to your ears skin, which makes it minimally invasive and now that the seeds are made of metals or even crystal, they can also be a bit of a fashion accessory because they look nice while you wear them. Ear seeds are also relatively low cost.

Beginner's set with applicators

Multi-Condition Ear Seeds Kit

$12.99

Top-rated crystal ear seeds

Crystal Ear Pellet Seeds

Includes manual and acupressure chart

Multi-Condition Ear Seeds Acupuncture Kit

$19.99

Best-selling refill kit

Ear Seed Acupressure Kit (10 Sheets)

$6.99

According to those who practice traditional Chinese medicine, there are centuries of anecdotal evidence that it is effective for treating or at least easing the symptoms of many physical and psychological ailments. Thats why in 1957, Paul Nogier, a French physician, adopted the practice and published the ear map to help those in the west adopt the practice.

Unfortunately, though, there arent many large medical studies that have been published to back up the discussion of these benefits with direct correlation to ear seeds. Many smaller-scale studies, however, conducted independently have suggested that ear seeding may ease the pain on an individual basis.

A small 2013 study, for example, found that ear seeding could help reduce low back pain and improve mobility, while a 2015 study found the practice might increase pain tolerance. An older 2010 study shared in the Journal of Alternative Medicine also found ear seeding might relieve mild to moderate pain and a 2020 review of 14 other studies from Brazil found ear seeds could effectively reduce musco-skeletal pain. A 2021 study in the Journal of Personalized Medicine, meanwhile, found it could ease menstrual pain, causing people to need fewer pain medications.

Other studies have supported some of the other holistic health claims that ear seeding aficionados have floated in the past:

Still, says Ingegno, ear seeding works best on people who have moderate symptoms who are looking for simple relief and not expecting miracles. In addition, many people also find that it benefits them most when it is practiced alongside regular traditional acupuncture sessions.

The short answer? Yes! Ear seeds are generally considered safe to use as they are topically applied with little to no invasive materials used. There may be some application risks, however, that you should be aware of.

Some people are sensitive to the adhesive used to apply the seed (particularly if they have a latex allergy) or the metal of the seed itself, Gosse explains. This can cause some itching, discomfort or redness all signs that you should remove the ear seed right away.

Youll also want to avoid ear seeds if you have cracks, scratches or other injuries to your skin as the seeds could aggravate those injuries further.

In addition, Ingegno says, you dont want to leave them in place too long as you may develop a divot in the skin where the ear seed was placed.

Ear seeds generally stay in place pretty well but there is a small possibility they can fall off and fall into your ear canal, which could cause injury to your ear or lead to an infection. In 2015, the scientific community shared a record of what happened to a woman after the seed fell through a hole in her eardrum and had to be surgically removed.

You can buy ear seeds from an acupuncturist near you, which is recommended for ear seeding newcomers, as they often provide instruction or any of the products available online.

Consumer kits like the ones available from earseeds.com come with instructions, a chart of the relevant points and tweezers, Ingegno says.

That said, all the acupuncturists we spoke with recommended talking with a professional before trying ear seeds for the first time by yourself.

[If you] have your first treatment from a professional acupuncturist, they can help you decide which points are best for you, says Laura Erlich, acupuncturist and womens holistic health specialist with Mother Nurture Wellness in Los Angeles. They can also mark points in your ear with a skin-safe marker to make it easier for you to do at home.

Just make sure that while youre applying them, you use a mirror and tweezers to apply the seed to your ear, while consulting a diagram of the acupuncture points in your ear. Be aware that everyones ears have different shapes and that you might need to adjust placement based on the shape of your ear, Ingegno explains. Dont expect your ear to look exactly like the picture in the product's chart [and] dont stress about getting them perfect.

Given the variation in everyones ears, finding the perfect location may seem impossible so aim for close enough, he adds.

When its time to take them off, use a tweezer and tilt your head towards the ground so the seed doesnt accidentally fall into your ear canal.

You might also want to give your ears short breaks between ear therapy treatments so that the skin doesnt get aggravated over time. Some experts believe they stop being as effective when worn consistently. Ideally you want to change your seeds out every 3 days, as the body will get used to the pressure, says Subotich. I generally will leave my seeds in for no more than 5-7 days and then give my ears a break for a day or two.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read this article:
Ear Seeds: What Is Ear Seeding and How Does It Work? Experts Explain - Good Housekeeping

2020 | MIT Technology Review

Novel drugs are being designed to treatunique genetic mutations.

Heres a definition of a hopeless case: a child with a fatal disease so exceedingly rare that not only is there no treatment, theres not even anyone in a lab coat studying it. Too rare to care, goes the saying.

Thats about to change, thanks to new classes of drugs that can be tailored to a persons genes. If an extremely rare disease is caused by a specific DNA mistakeas several thousand aretheres now at least a fighting chance for a genetic fix.

One such case is that of Mila Makovec, a little girl suffering from a devastating illness caused by a unique genetic mutation, who got a drug manufactured just for her. Her case made the New England Journal of Medicine in October, after doctors moved from a readout of her genetic error to a treatment in just a year. They called the drug milasen, after her.

The treatment hasnt cured Mila. But it seems to have stabilized her condition: it has reduced her seizures, and she has begun to stand and walk with assistance.

Milas treatment was possible because creating a gene medicine has never been faster or had a better chance of working. The new medicines might take the form of gene replacement, gene editing, or antisense (the type Mila received), a sort of molecular eraser, which erases or fixes erroneous genetic messages. What the treatments have in common is that they can be programmed, in digital fashion and with digital speed, to correct or compensate for inherited diseases, letter for DNA letter.

How many stories like Milas are there? So far, just a handful.

But more are on the way. Where researchers would have once seen obstacles and said Im sorry, they now see solutions in DNA and think maybe they can help.

The real challenge for n-of-1 treatments (a reference to the number of people who get the drug) is that they defy just about every accepted notion of how pharmaceuticals should be developed, tested, and sold. Who will pay for these drugs when they help one person, but still take large teams to design and manufacture?

See original here:
2020 | MIT Technology Review

Novus Anti-Aging Center Los Angeles | Erectile Dysfunction …

Novus Anti-Aging Center Los Angeles | Erectile Dysfunction Clinic

Welcome to the orgasm clinic! If your sex life is anything short of amazing, come see us for a free consultation. We offer innovative and non-invasive procedures that are proven to be effective up to 90% without the use of medications or risky surgeries.

Stephanie is the nations leading sexual wellness expert, the co-founder of Launch Medical, co-inventor of The Phoenix, a Board Certified Anti-Aging Specialist, Hormone Expert, and Peptide Expert with the American Academy of Anti-Aging Medicine,a Board Certified Physicians Assistant, and aCertified Weight Loss Specialist with the National Academy Of Sports Medicine.She graduated from Arizona State University in 2000 with her Bachelor of Science in Life Sciences and continued on to Midwestern University where she obtained her degree as a Physician Assistant.

At Novus Anti-Aging Center, we provide treatments for male and female hormone mastery for our Los Angeles patients. Our specialists have helped harmonize hormones and happiness for hundreds of mature patients who are now living the high life (with a revived love life).

The Novus Center Answers Your Most Asked Questions about Sexual Performance

If you've suffered from vaginal laxity for quite some time, you may have thought revival was impossible. In the past, women had no choice but to bear the effects of childbirth and make the most of it, but those days are long gone - now, Viveve is empowering women to take back their vibrant sexuality on their own terms.

Your sex life - regardless of your age - might have taken a nosedive because sex has become painful or unexciting due to lack of arousal. The O-Shot is a revolutionary nonsurgical treatment that uses a patient's own blood platelets to activate growth factors that rejuvenate the female orgasm system.

This site uses cookies to make the site simpler. Further information is provided in our Privacy Policy.

Read the original here:
Novus Anti-Aging Center Los Angeles | Erectile Dysfunction ...

The Dog Aging Project digs deeper than ever to help our best friends live better longer and the findings could help us, too – The Spokesman Review

SEATTLE If it werent for squirrels, Bagel probably wouldnt be here today at Washington State Universitys College of Veterinary Medicine. The yellow Labrador was destined to be a guide dog for the blind but flunked out because she was distracted by small animals. Now, this otherwise very good girl has a second chance to be of service by participating in the most comprehensive study ever conducted of health and aging in dogs.

Bagels owner, Brenda Voght, volunteered her to join a research pack that already includes more than 37,000 pet dogs across the country and is expected to swell to 100,000. Called the Dog Aging Project, the ambitious undertaking seeks to answer many of the questions dog owners ask and often anguish over: Why do some breeds live longer than others? How do genetics, environment and lifestyle affect longevity and the risk of disease? And, above all: How can we ensure our beloved companions stay healthy, happy and active for as long as possible?

I would like to know if there is something we can do as humans, as their partners, to extend their lives a little longer, says Voght. After her last dog died, it was a year before she was able to open her heart to another puppy.

She fostered Bagel for about a year, then adopted her after the canines career change the gentle euphemism used when guide dogs dont make the cut.

On average, yellow Labs live 10 to 12 years.

Bagel is 9.

The project welcomes dogs of all types and ages and plans to track them for at least 10 years, says Daniel Promislow, an evolutionary geneticist at UW Medicine who co-founded the initiative and helped assemble a national team of more than 80 researchers, veterinarians and data scientists to coordinate the massive undertaking.

No one has ever investigated such a large number of dogs over such a long period of time, especially at the level of detail Promislow and his colleagues envision. One branch of the study is sequencing the genomes of at least 10,000 dogs. Another zeros in on the oldest dogs in the pack the supercentenarians to look for keys to their longevity.

All of us are really excited about what will come out of it, says Elaine Ostrander, who pioneered genetic analysis of dogs more than two decades ago in Seattle at the Fred Hutchinson Cancer Research Center. She now works at the National Human Genome Research Institute.

Its long been clear that big dogs have shorter lifespans than small dogs, and that different breeds are predisposed to different ailments, says Ostrander, who is not involved in the project. Golden retrievers are prone to cancers. German shepherds often develop hip dysplasia. Doberman pinschers have a high prevalence of heart disease. The Dog Aging Project will help reveal more about the mechanisms behind those links, she says.

Theyre going to be able to make those connections pretty tightly because their data set is the biggest one out there.

The researchers also hope to gain insights into normal aging, along with the entire spectrum of ailments that plague older dogs, from arthritis and hearing loss to cataracts and cognitive decline. Discovering ways to help dogs live longer would be wonderful, says Promislow. But the primary goal is to prolong health span that golden period of well-being when dogs can leap and dive and fetch and snuggle free from pain or disability.

We want to help each dog live the longest, healthiest lifespan that it can, he says.

The findings could be relevant to human health as well.

Dogs suffer from many of the same diseases we do. And unlike mice and other animals used in laboratory studies, dogs are genetically diverse. They live in our homes, breathe the same air and experience the same conditions.

The sad fact that dogs lives are shorter than ours means its possible to gain that knowledge more quickly by focusing on humanitys best friends.

Most of the animals enrolled in the Dog Aging Project never have to leave their home turf. Owners fill out an annual, 116-page questionnaire that covers everything from diet and mobility to temperament, favorite types of toys, bowel habits, pesticide exposure, health status and sleeping arrangements. Environmental data, like air and water quality, is correlated to each dogs geographic location. Participants also can upload their dogs veterinary records, and more than 15,000 already have done so.

Dog owners are integral to the project, which keeps them in the loop with blog posts and a dedicated social media platform called the Dog Park. Its the kind of science that cuts across politics, demographics and geography because so many Americans are crazy about dogs, Promislow says.

Im really excited about the ability to bring science to the lives of people in a way thats fun and informative and educational.

A small subset of canines are candidates for more intensive study, which is why Voght made the drive from her home in Bothell to the other side of the state. Bagel is being evaluated for the most high-profile arm of the project: a clinical trial of a potential anti-aging drug.

Called rapamycin, the medication is used in human transplant patients to prevent organ rejection. But studies in yeast, worms and mice show that low doses can extend lifespan by up to 25%. Rapamycin also delays age-related maladies such as cognitive decline and cancer, and boosts heart health in mice.

Dr. Kate Creevy, chief veterinary officer for the project, is optimistic it might do the same for dogs. In one small trial, dogs who got the drug showed improved heart function. In another, owners said their dogs seemed more active.

Now, the team is recruiting 500 senior dogs for a year of treatment and two years of follow-up. Half the dogs will get rapamycin, and half will get a placebo. Neither owners nor scientists will know which until the end.

Even if we dont actually change lifespan, if we improve the experience of aging, that will be really, really valuable to dogs and the people who love them, says Creevy, of Texas A&M University.

The dogs in the study need to be healthy, so Bagel is getting the type of checkup available only in a veterinary teaching hospital such as WSUs. Staff leads her into an exam room, where she obligingly hops on the table and rolls onto her side.

Technicians shave a small patch of fur for analysis, draw blood, measure blood pressure and attach electrodes to monitor her heartbeat. Dr. Ryan Baumwart, a veterinary cardiologist, checks Bagels eyes and probes her heart with ultrasound, displaying the image of the beating organ on a wall-mounted computer screen.

The study is just getting started, and, so far, only about half of dogs examined have qualified. Bagels scans look promising, Baumwart says. Now, its a matter of waiting on the blood tests.

The dog aging project reflects a new approach to the most common causes of death in canines and people, says co-director and UW Medicine pathologist Matt Kaeberlein, who studies the basic biology of aging. Most research focuses on specific diseases, such as cancer or Alzheimers. But nearly all of the major killers are strongly linked with age, so Kaeberlein argues that it makes sense to focus on the aging process itself.

If we can understand aging biology and what it is at a cellular, molecular, mechanistic level, then maybe it will be feasible to target that biology with interventions, he says. Those might be nutritional strategies, drugs or gene therapy, with the goal of lowering the risk of all age-related diseases.

For example, rapamycin seems to work at least in part by reducing inflammation, which increases with age and impairs immune function. Older animals also accumulate more cellular debris, and rapamycin revs up the process of clearing it away.

Another arm of the project, called the Precision Cohort, will delve in unprecedented detail into biochemical changes and shifts in gene expression over time in 1,000 dogs.

We will know more about the biology and physiology of those dogs than probably anybody has ever known about dogs before, Kaeberlein says. We will be collecting very high-resolution data to try to understand the relationship between their unique genetic makeup and their unique environment thats influencing the aging process.

One of those dogs is Hana, a 3-year-old Cavalier King Charles spaniel with long, silky ears who lives on Bainbridge Island. Her owner, Masami Shimizu-Albergine, is a researcher herself and was eager to help.

Once a year, Hanas vet collects blood, urine, feces and hair samples for analysis at specialized labs. Its a level of medical monitoring few humans receive, and it will help pin down the role of gut microbes, metabolic function, toxin exposure and a host of other factors.

Theres really no end to what we can discover, Promislow says.

Analyzing the genomes of 10,000 dogs will uncover the genetic basis for a large swath of canine diseases, says Joshua Akey, a geneticist who started working on the dog project at the University of Washington and is now at Princeton Universitys Lewis-Sigler Institute for Integrative Genomics.

As in humans, though, its not likely to be simple. Most diseases result from multiple genes and environmental factors. But Akey says it should be possible to develop risk scores to alert owners to their dogs genetic predispositions. One UW researcher is focused on dogs with lymphoma, looking for a genetic biomarker for early diagnosis.

The link between a dogs size and lifespan appears to have a strong genetic basis. Big breeds have higher levels of a protein called IGF-1 (insulin-like growth factor), which is involved in regulating growth. In mouse studies, dialing down that protein can extend life and improve health.

So even though it might be possible to improve health for all dogs, a 150-pound Great Dane likely will never match the longevity of a 15-pound Chihuahua, Creevy says.

Distinct breeds were developed only in the past few centuries, and the trove of genetic information compiled for the project will help retrace that process. It could even settle the debate over when wolves were first domesticated and morphed from Canis lupus to Canis familiaris.

Some people say it was 10,000 years ago, and others have argued it was much longer, Akey says. I think well have a data set that can definitively answer some of these evolutionary questions.

Promislow, Creevy and Kaeberlein started kicking around the idea of a major dog study more than a decade ago. It took years to lay the groundwork and convince federal funders of its worth. Their first major grant $25 million from the National Institutes of Aging was awarded in 2018. The team also has funding from foundations, tech entrepreneurs and small donors such as the Irish wolfhound Association of New England.

All of the data will be freely shared online. The first batch, from about 25,000 dogs, was recently posted and already is showing some intriguing correlations. For example, dogs fed once a day appear to have higher cognitive scores and fewer health problems than dogs who eat multiple times a day.

That doesnt prove cause and effect, Kaeberlein cautions, but its a place to start digging deeper.

The project also has the potential to provide some of the best comparisons of dog diets, which now come in a dizzying array, from dry kibble to small-batch artisan concoctions. Promislow, who never imagined he would be cooking for a dog, started preparing a mix of sweet potatoes, oats, ground chicken and kibble for Frisbee, his 16-year-old mixed-breed female, after she was stricken with severe diarrhea.

We can do the careful science to evaluate the effects of raw-food diets, home-cooked diets, et cetera, he says. We will soon have more data than any other study on the consequences of a grain-free diet.

The project is nonprofit, but entrepreneurs are keen to apply the information it generates. Americans spent almost $104 billion on pet care in 2020, and the trendline points up, according to the American Pet Products Association.

Startups already are chasing more sophisticated genetic testing and anti-aging drugs for dogs. But they cant generate the massive amounts of data or conduct large-scale clinical trials like the Dog Aging Project does, says Celine Halioua, founder and CEO of Loyal. Kaeberlein is a scientific adviser to the Bay Area biotech, which is testing two drugs to increase health span in dogs.

The dog-aging database will be an invaluable resource, Halioua says.

Its a gift to the aging field for them to be doing this.

A week after the visit to WSU, Voght got the news: Bagel qualified for the rapamycin trial. Shell get a once-a-week dose, either real or placebo, for the next year, and physical exams every six months through 2025. Voght wont know until then whether Bagels pills are real. Either way, shes willing to keep making the trip to Pullman in hopes that the project will benefit Bagel, other dogs or even people.

Shes not expecting miracles, though.

Bagel is already slowing down a bit, and her face is frosted with white. If Labs can make it into the double digits, youre lucky, Voght says.

So she recently adopted what she calls her transition dog a 2-year-old black Lab named Delray.

Its nice to have another dog in the house to help you a little bit, she says. For when that time comes.

Go here to read the rest:
The Dog Aging Project digs deeper than ever to help our best friends live better longer and the findings could help us, too - The Spokesman Review

Anti-Aging Market Scope and overview, Growth Study, Future Trends, Demands, and Top Players Data by Forecast to 2030 POSTED IN : PRESS-RELEASE Ripon…

New York, United States

The global anti-aging market was valued at USD 149362.8 million in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2024, by value, reaching around USD 274290.1 million by the end of the forecast period. According to the report, North America was the largest contributor in terms of revenue to the global anti-aging market in 2017.

Request To Download Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=51553

Increase in the aging population is driving the global anti-aging marketIncreasing life expectancy and fall in birth rate are the major causes of an aging population. The aging population develops wrinkles due to lack of nutrients in the body, exposure to UV light, smoking, dehydration, medications and other genetic factors fueling the global anti-aging market.Globally, aging population plays a major role in the growth of the anti-aging market. Old age is associated with loss of fibrous tissue and reduced vascular and glandular network in the layers of skin. In the elderly population, the appearance and characteristics of the skin gets altered, leading to wrinkles, dryness, pigmentary alteration, and sagging of the skin. In addition, anti-aging products and devices help in reducing skin aging, thus giving younger look to a person by revitalizing and tightening the skin leading to the growth of the market

The key driver for the global anti-aging market is growth in anti-aging awareness campaigns. Major aspect of peoples life is engrossed by social media. This campaigns aims to ensure that all medical professionals are aware of the latest scientific research and the recent medical and surgical advances. For instance, EuroMediCom has organized the 4thAMWC Latin America- Aesthetic & Anti-Aging Medicine World Congress from 16th November to 18th November 2017, in Colombia, South America. These conference and seminars, along with social media, are expected to create awareness among students, delegates, and plastic surgeons about advanced anti-aging treatments.

Request Full Report :-https://reportocean.com/industry-verticals/sample-request?report_id=51553

Global Anti-aging Market: Scope of the Report

The global market for anti-aging is segmented by type of product, by type of device, by treatment, demography, and geography. The type of product is further segmented into Anti-Wrinkle, Hair Color, UV Absorbers, Anti-Stretch Marks and Others. The type of device is further segmented into Radiofrequency, Laser, Anti-Cellulite, and Microdermabrasion. Treatment segment is bifurcated as Hair Restoration, Anti-Pigmentation, Anti-Adult Acne, Liposuction, Breast Augmentation, Chemical Peel and Others.

Demography is segmented (Generation X, Baby Boomer, and Generation Y)Geographically, the global anti-aging market is bifurcated into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America anti-aging market was the most prominent market because anti-aging industry is one the major revenue contributor within the manufacturing industries. Thus, the demands for anti-aging products, like Anti-Wrinkle, Hair Color, UV Absorbers and Anti-Stretch Marks will generate higher revenue returns over the forecast period.

Global Anti-aging Market: Competitive DynamicsMajor industry players in global anti-aging market are adopting different strategic initiatives such as mergers and acquisitions, partnerships, and collaborations for strategic expansion in the anti-aging market. For instance, In January 2016, LOreal unveiled My UV Patch, the first-ever stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection.

Request Full Report :-https://reportocean.com/industry-verticals/sample-request?report_id=51553

Market Segmentation: Global Anti-aging MarketType of Product, Anti-Wrinkle, Hair Color, UV Absorbers, Anti-Stretch MarksType of Device, Radiofrequency, Laser, Anti-Cellulite, MicrodermabrasionBy Treatment, Hair Restoration, Anti-Pigmentation, Anti-Adult Acne, Liposuction, Breast Augmentation, Chemical Peel, OthersBy Demography, Generation X, Baby Boomer, Generation YBy Region, North America, Europe, Asia Pacific, Latin America, Middle East & Africa

What are the key findings of the report?

This report provides comprehensive information on factors expected to influence the market growth and market share in the future.The report offers the current state of the market and future prospects for various geographical regions.This report provides both qualitative and quantitative information about the competitive landscape of the market.

Access full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=51553

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com/

See more here:
Anti-Aging Market Scope and overview, Growth Study, Future Trends, Demands, and Top Players Data by Forecast to 2030 POSTED IN : PRESS-RELEASE Ripon...

Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness -…

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage. Similar to the companys recently announced pipeline expansion into auditory neurons for the treatment of hearing loss, Lineage has filed for intellectual property protection covering the composition and methods for generating PNCs. Based on recent in vivo data generated using the companys PNCs, these cells may be capable of forming reconstructed retina with high survivability and neural connectivity to surrounding functional layers. Notably, Lineage has demonstrated feasibility which could support a large-scale method for producing both types of photoreceptors, known as rods and cones.

It is natural that, on the heels of the announcement of our alliance with Roche and Genentech for our RPE cell therapy, a deal worth up to $670 million dollars plus double-digit royalties if certain development, approval, and sales milestones are achieved and other conditions are met, that we also would pursue treatments for vision loss through the other major cell type of the retina, the photoreceptors, stated Brian Culley, Lineages CEO. Our fundamental technology and accumulated know-how give us the opportunity to make many different cell types, and we have demonstrated our ability to create new programs rapidly and efficiently in two distinct areas, expanding our cell therapy pipeline to five separate preclinical and clinical programs, while still maintaining what we believe is an appropriate and responsible rate of investment for a company of our size. This latest program is part of our long-term planning for clinical and commercial success and serves as another example of the capability of our technology platform. We believe our ability to, in just a matter of months, advance from a product concept to generating new intellectual property and manufacturing the desired cell types, is illustrative of the power and efficiency of our platform. We believe the combination of our capital discipline and current balance sheet will support multiple years of further progress, during which we anticipate reaching achievements with each of our clinical and preclinical programs.

Dr. Rami Skaliter, who leads the manufacturing function for Lineage, added, Im exceptionally proud of the teams success at overcoming obstacles related to the limited scale of photoreceptor production. Building upon our experience with other cell lineages, we have developed intellectual property, and filed for patent protections, on a manufacturing process which is compatible with large-scale production of photoreceptors in a closed system, improvements which could enable industrial manufacturing. We believe this accomplishment will provide new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need such as Retinitis Pigmentosa, Stargardts Macular Dystrophy, and retinal detachments, either independently or through strategic alliances.

As part of a scientific collaboration with Professors Benjamin Reubinoff, M.D., Ph.D. and Eyal Banin, M.D., Ph.D., of the Hadassah-Hebrew University Medical Center, the differentiation of pluripotent cells into photoreceptors with clinically compatible characteristics was established utilizing a novel differentiation protocol which generated positive identity of key markers of both rods and cones photoreceptor populations. The data generated by the company further demonstrated that a single cell suspension of photoreceptor precursor cells has the potential to survive and mature post-transplantation in a rodent model of retinal degeneration.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include five allogeneic (off-the-shelf) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit http://www.lineagecell.com or follow the company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, aim, may, will, estimate, continue, anticipate, design, intend, expect, could, can, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to (i) the potential amount of payments to Lineage under the alliance with Hoffman-La Roche Ltd. (Roche) and Genentech, Inc., (ii) the potential for new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need, (iii) Lineages position to become a leader in the emerging field of regenerative medicine and anti-aging technology, and (iv) future areas of potential treatment using PNC transplant. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the payments payable to Lineage under the Roche/Genentech collaboration and license agreement, the risk that Roche/Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; the risk that Lineage might not succeed in developing products and technologies that are useful in medicine and demonstrate the requisite safety and efficacy to achieve regulatory approval in accordance with its projected timing, or at all; the risk that Lineages intellectual property may be insufficient to protect its assets; risks and uncertainties inherent in Lineages business and other risks discussed in Lineages filings with the Securities and Exchange Commission (SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

See the original post:
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness -...

Health and Wellness Market to Exceed US$ 6.94 Trn by 2031; Companies Expanding Range of Skincare Products to Capture Steady Revenues, Observes TMR…

ALBANY, N.Y., April 26, 2022 (GLOBE NEWSWIRE) -- Relentless focus on expanding the portfolio of skincare and anti-aging products have pivoted several lucrative avenues in the health and wellness market. In recent years, especially after the outbreaks of COVID-19 pandemic, the emphasis on wellness has gained strong momentum, spurring industry stakeholders to tap into new revenue streams. The global health and wellness market valuation was pegged at more than US$ 4.1 Trn in 2020, and is projected to exceed US$ 6.94 Trn by 2031.

The growing commercialization of multi-functional personal care products such as for skincare and hand care has propelled revenue possibilities, finds an in-depth TMR study on the health and wellness market. The authors of the study also assert that hand care premiumization is a trend that has picked up enormous pace in emerging markets such as in Asia Pacific. Furthermore, the upsurge in sales of alcohol-based hand sanitizers and skincare products for all demographics has contributed to the rapidly expanding size of the health and wellness market.

Personal care product manufacturers over the years have geared toward adopting eco-friendly packaging materials and sustainable sourcing and manufacturing processes, thus expanding lucrative frontiers in the health and wellness market. Further, in several of the hygiene products, health-promoting ingredients are expanding the avenue for these players.

Request Brochure of Health and Wellness Market Research Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=450

Key Findings of Health and Wellness Market Study

Request for Analysis of COVID-19 Impact on Health and Wellness Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=450

Health and Wellness Market: Key Drivers

Get Exclusive PDF Sample Copy of Health and Wellness Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=450

Health and Wellness Market: Regional Growth Dynamics

Health and Wellness Market: Key Players

Some of the key players in the health and wellness market are Healing Holidays (Cleveland Travel Ltd.), BodyHoliday Saint Lucia, Lift Brands, Anytime Fitness LLC, Herbalife Nutrition Ltd., Abbott Laboratories, BioThrive Sciences, Unilever plc., L'Oral S.A., The Este Lauder Companies Inc., and Anti-ageing Facial Tools.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=450

Global Health and Wellness Market: Segmentation

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research:

Sexual Wellness Market: Global health organizations and efforts of voluntary organizations for the betterment of women health in underdeveloped countries are also stoking the demand for sexual wellness products, especially sex toys. These organizations conduct adult health awareness workshops periodically for preventive care.

Wellness Tourism Market: The rising demand for services from the global wellness tourism market can be attributed to rising demand for healthy living, stress reduction, gaining authentic experiences, preventing diseases, and managing and changing poor or toxic lifestyle habits or choices.

Health & Wellness Services Market: Rise in awareness about health and wellness services among employers, increase in health care costs, and surge in incidence of chronic diseases are driving demand for health and wellness services in the corporate segment and increasing investments in corporate wellness programs. These factors are expected to drive the global health & wellness services market during the forecast period.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey

Transparency Market ResearchState Tower,90 State Street, Suite 700,Albany NY 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comFollow Us: Twitter | LinkedInBlog: https://tmrblog.comBrowse PR - https://www.transparencymarketresearch.com/pressrelease/health-and-wellness-market.htm

Continued here:
Health and Wellness Market to Exceed US$ 6.94 Trn by 2031; Companies Expanding Range of Skincare Products to Capture Steady Revenues, Observes TMR...

UPMC Children’s Hospital Foundation Receives $1 Million Gift from Alba Tull to Benefit Children’s Neuroscience Institute – UPMC

4/21/2022

PITTSBURGH UPMC Childrens Hospital Foundation today announced it has received a $1 million gift from Alba Tull to advance pediatric neuroscience research, education and patient care at UPMC Childrens Hospital of Pittsburghs Childrens Neuroscience Institute (CNI).

The gift builds upon Tulls deep commitment to neurological research, specifically in the greater Pittsburgh area. Last year, she worked with the University of Pittsburgh School of Medicine to create the Alba Tull Center for Neuro Imaging and Therapeutics. The Center is dedicated to designing and expanding imaging technologies for patient care to produce a new, sophisticated understanding of the brain to develop anti-aging therapeutics. Todays gift will now help bring that same commitment of pursuing innovative neuroscience research and treatment to children.

The past few years have truly highlighted that medicine is the backbone of our future, which is why supporting leading research and developments in health care especially for those who are most precious, children is one of my top priorities, said Alba Tull, philanthropist and founder of First Light Capital Group. I continue to be inspired by UPMC Childrens work, especially in neuroscience. I am proud to continue to support and work alongside CNI as they continue to make monumental advancements in their innovative research and new discoveries for pediatric neuroscience.

Tull is a long-time supporter of UPMC Childrens. Her involvement began several years ago with her gift to support research and Creative and Expressive Arts Therapy, and she has long served as a member of UPMC Childrens Foundations Board of Trustees. Her involvement with CNI began last year when she pledged her support for the hospital during its DVE Rocks Childrens Radiothon. After meeting with several neuroscience and research leaders at UPMC Childrens, she decided to designate the donation for CNI.

Todays children are tomorrows future, and we are tremendously grateful for the generous support from Alba Tull, who is advancing our vision to build a premier destination for pediatric neuroscience research, education, and care, said Terence Dermody, M.D., chair of pediatrics at UPMC Childrens. We are thrilled about the research this gift will enable CNI to undertake. Funding for pediatric research, including childrens brain health, is an area of tremendous need. This extraordinary gift will help us fulfill our mission, investing in the science of brain health and disease that will improve the lives of children in Pittsburgh and throughout the world. We are very thankful to Alba Tull for continuing to support the important work of our team and hospital.

The largest donation in CNIs history, the gift will provide flexible research funding to address some of the most pressing priorities of the program, including research infrastructure, pilot grants, and training future leaders, all of which will help generate new breakthroughs in pediatric neuroscience. In particular, it will be used to help progress the understanding of neurological illness, discover and develop personalized therapies for children with neurological diseases or impairments, as well as innovate diagnostic medicine and find ways to translate research directly to patients.

CNI continues to grow and make cutting edge-advancements in the field of neurological disorders. To that end, the research team will continue to prioritize connectivity, neurodevelopment, neonatal and fetal stroke, and lipidomics, a new and quickly growing field of research.

CNI is led by Hlya Bayr, M.D, an award-winning and international leading physician-scientist who has spent decades studying pediatric neurocritical care and traumatic brain injury. With the support from Alba Tull, Bayr will be equipped to bolsters CNIs efforts towards translating innovative research more quickly to patients.

About UPMC Childrens Hospital Foundation

UPMC Childrens Hospital Foundation is the catalyst that unites communities and contributors to create healthier futures for all children through life-changing care and cutting-edge research. As the sole fundraising arm of UPMC Childrens Hospital of Pittsburgh, we support their vision of being the world leader in pediatric health care, education, and discovery. The Foundation is a public charity under 501(c)(3) and 170(b)(1)(A) of the Internal Revenue Service Code. For more information, visit http://www.givetochildrens.org

About Alba Tull

Alba Tull is a leading female philanthropist, accomplished multi-disciplined photographer and film producer, and leading investor. She is the founder and Managing Director of the First Light Capital Group, the technology-informed investment firm and female entrepreneur seeder. She also serves as the chairperson of Tull Investment Group, a privately held investment fund that manages an array of real estate holdings and interest in companies including Genies, Pinterest, Zoox, and Oculus Rift.

Outside of her professional work, Tull is the chair of her familys philanthropic organization, the Tull Family Foundation (TFF), and serves on the board of many leading organizations, including UPMC Childrens Hospital Foundation, the Pittsburghs Carnegie Science Center, The Rett Syndrome Research Trust and The Jackie Robinson Foundation. She is also a member of Carnegie Mellon Universitys Highlands Circle and is a life-long supporter of the United States Navy, where she is currently serving as the sponsor of the next-generation ship, the USS Cooperstown LCS 23.

View post:
UPMC Children's Hospital Foundation Receives $1 Million Gift from Alba Tull to Benefit Children's Neuroscience Institute - UPMC

The Truth Behind Trendy IV Vitamin Therapy – AARP

But experts say there is little scientific evidence backing the treatments. They also caution that medically unnecessary IV drips could be risky for some people particularly those who have heart disease or kidney problems.

For these individuals, getting too much fluid too fast could be harmful because their heart or kidney cant tolerate a lot of salts and fluids being introduced into their bodies, says Sam Torbati, M.D., co-chair of the Department of Emergency Medicine at Cedars-Sinai Medical Center in Los Angeles. Medically speaking, thats where there is the most potential for harm.

He recommends checking with your medical provider before visiting a drip clinic.

An IV can be lifesaving for a patient who is severelydehydrated, nutrient deficient or suffering from a massive infection. But many experts say theres no reason to get what is essentially an invasive treatment unless a doctor recommends it.

IV hydration is a great thing for people who really need it, says Robert H. Shmerling, M.D., senior faculty editor of Harvard Health Publishing, who has researched IV therapy. When it comes to these IVs on demand, the short answer is, Buyer beware. They are expensive and not clearly helpful in any scientific, proven way.

While its true that an IV can hydrate you faster than drinking fluids by mouth, Shmerling says, that doesnt necessarily translate into any kind of health benefit.

Onereview studypublished in the journalSports Healthfound no evidence that IV fluid administered to athletes enhanced performance or helped them rehydrate any better than oral fluids.

If youre able to drink fluids and your digestive system is working thats the best way to get them, Shmerling says.

If youre too sick or elderly to keep up with your bodys need for fluids by drinking, then you should be in a medical facility, he adds.

The claims for IV therapy go beyond simple hydration, however. At most clinics, you can choose from a selection of concoctions, depending on your goal. There are different cocktails to cure a hangover,boost the immune system, improve energy, help with workout recovery, treat jet lag, improve skin, remove toxins and reverse the signs of aging.

There is little evidence to back any of those benefits, Shmerling says, and the clinics are not regulated by the Food and Drug Administration. The marketing has gotten way out ahead of the science.

In fact, most clinics include some variation of this disclaimer on their website and in marketing materials: The services provided have not been evaluated by the Food and Drug Administration. Any designations or references to therapies are for marketing purposes only.

One of the few controlled clinical studies that looked at IV vitamin therapy compared to a placebofound that patients with fibromyalgiareported less tenderness and pain after receiving a specific infusion called a Myers Cocktail, a mix of magnesium, calcium, and vitamins C and B invented by a physician named John Myers.

But heres the catch: Patients in the study who were injected with just saline solution reported the same positive results a sign of a strong placebo effect, the studys authors wrote.

If you decide to try IV therapy, make sure youre getting the treatment in a safe, clean environment. Also ask who will be administering your IV and how much experience they have, Torbati advises.

Because you are getting a needle placed in your arm, there is a chance of pain or bruising or, in rare cases, infection or inflammation of the vein. Older patients tend to have smaller veins, so placing an IV in someone over age 65 is more difficult than in a younger person. The more frail and medically complex you are, the more cautious I would be about trying these things, Torbati says.

Its also important to ask exactly what substances will be going into your body.

Some drips have anti-inflammatory or anti-nausea medications that could cause an allergic reaction orinteract with drugs a patient is currently taking, Torbati says. Other infusions include prescription drugs such as ketorolac and lidocaine that could lead to life-threatening adverse effects in some patients, according to a 2014 study published in theJournal of Parenteral and Enteral Nutrition.

In 2018, supermodel Kendall Jenner was hospitalized after a bad reaction to a Myers Cocktail vitamin IV drip, according to news reports.

Although IV drips are low risk for most healthy people, medical experts generally recommend against them mostly because theyre expensive and unnecessary. The cost of a vitamin drip ranges from a $79 first-time special at some clinics to hundreds of dollars for a special cocktail delivered to your home by a mobile provider.

Theres nothing magical about getting vitamins in an IV, Torbati says. If you want extra nutrition,take a vitamin. If you have a headache, take a Motrin. Instead of spending hundreds on an IV, you can spend a nickel on a pill and get the same benefit.

Michelle Crouch is a contributing writer who has covered health and personal finance for some of the nations top consumer publications. Her work has appeared inReaders Digest,Real Simple,Prevention,The Washington PostandThe New York Times.

Read the original:
The Truth Behind Trendy IV Vitamin Therapy - AARP

Traditional Chinese Herbal Medicine For Face-Care Market To Surpass Valuation Of US$ 1.1 Bn By 2031, Increase in Generic Population to Drive the…

Traditional Chinese Herbal Medicine for Face-care Market: Introduction

According to the report, thetraditional Chinese herbal medicine for face-care marketin Asia Pacific was valued at US$569.29Mn in 2020 and is projected to expand at a CAGR of7.1%from 2021 to 2031. Traditional Chinese Herbal Medicine (TCHM) is part of a larger healing system called Traditional Chinese Medicine. Herbs are prescribed to restore energy balance to the opposing forces of energy Yin and Yang that run through invisible channels in the body. Rise in entry of pharmaceutical companies and increase in the geriatric population are anticipated to drive the traditional Chinese herbal medicine for face-care market in Asia Pacific.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84584

China held major share of the traditional Chinese herbal medicine for face-care market in Asia Pacific in 2020 due to rise in awareness among people and increase in the geriatric population. The market in India is likely to expand at a high CAGR of 9.1% from 2021 to 2031. Rise in adoption of traditional Chinese herbal medicine for face-care in India and other countries in Southeast Asia is projected to fuel the growth of the market in Asia Pacific from 2021 to 2031.

Others Segment Dominated Global Market

In terms of benefit, the traditional Chinese herbal medicine for face-care market in Asia Pacific has been classified into anti-aging, brightening (whitening), firming, reducing fine lines, anti-oxidation, hydration, sensitive skin (anti-acne, anti-irritation), and others. The others segment dominated the traditional Chinese herbal medicine for face-care market in Asia Pacific in 2020.

Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=84584

China to Lead Asia Pacific Market; India to Offer Significant Opportunities

In terms of country, the traditional Chinese herbal medicine for face-care market in Asia Pacific has been segmented into China, South Korea, Japan, India, Thailand, Indonesia, and Rest of Asia Pacific. China is anticipated to account for leading share of the traditional Chinese herbal medicine for face-care market in Asia Pacific during the forecast period. The market in India is expected to grow at a rapid pace in the near future.

Growth Strategies of Key Players

Key players operating in the traditional Chinese herbal medicine for face-care market in Asia Pacific are Eu Yan Sang, Integrated Chinese Medicine Holdings Ltd., Shanghai Jahwa United Co., Ltd, Solstice Medicine Company, Inc., The Mentholatum Company (ROHTO Pharmaceutical Co., Ltd.), and Yunnan Baiyao Group Co., Ltd. The traditional Chinese herbal medicine for face-care market in Asia Pacific is fragmented due to the presence of large number of international and local players.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=84584

Asia Pacific Traditional Chinese Herbal Medicine for Face-care Market: Segmentation

More Trending Reports by Transparency Market Research:

Hyaluronic Acid Products Market: Hyaluronic acid supplements are highly useful for people suffering from orthopedic disorders, such as osteoarthritis a type of degenerative joint disease caused by wear and tear on the joints over time. Hyaluronic acid could also be injected directly into the joints in order to gain pain relief. The hyaluronic acid market primarily thrives on the aging population who are highly susceptible to bone injuries, incontinence, and fractures.

Point-of-Care Diagnostics Market: According to the report, the globalpoint-of-care diagnostics marketwas valued at US$34.1Bn in 2020 and is projected to expand at a CAGR of4.7%from 2021 to 2028. Point-of-care diagnostic test is carried out close to or near the patient location for analysis of health condition as well as presence of infectious diseases.

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information.Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Upfor a 7 day free trial!

Contact Us

Rohit BhiseyTransparency Market Research,90 State Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: [emailprotected]Website:https://www.transparencymarketresearch.com/

View post:
Traditional Chinese Herbal Medicine For Face-Care Market To Surpass Valuation Of US$ 1.1 Bn By 2031, Increase in Generic Population to Drive the...

Seek health and well-being at wellness tourism destinations – The Korea Herald

A View from Seolhaeone Resorts infinity pool in Yangyang, Gangwon Province (KTO)

In 2020, the global wellness tourism market was estimated at 908 trillion won ($735.8 billion), according to the GWIs Wellness Tourism-Global Market Trajectory and Analytics report, published in April 2021. This is a 15 percent increase from some 790 trillion won recorded in 2017.

The report also forecasts the wellness tourism market to reach 1,479 trillion won by 2027.

So-called retreat centers are freshly gaining popularity in Korea after the pandemic, Choi Hee-jeong, professor at Cha Universitys Graduate School of Integrative Medicine, told The Korea Herald.

Jeju 901, a brunch cafe and guest house, offers regular yoga sessions in Jeju City, Jeju Island. (KTO)

The wellness tourism recommendation project, which was initiated in 2017, reflects travelers growing demand for tourism that links to themes of enhancing physical, mental, and emotional health.

This years list consists of 59 locations recommended for wellness tourism.

The selected sites fall under one of four main categories: beauty and spas, nature and forest, healing and meditation as well as Asian medicine.

The beauty and spa category includes beauty therapy programs and facilities such as hot springs. This year, the East Coast Energy Hot Springs Convention Hotel in Donghae, Gangwon Province, Seolhaeone Resort in Yangyang, Gangwon Province, and S2 Beau Tech Lounge in Daegu were chosen.

Jeju Hwansang Forest Gotjawal Park, a farm-turned-forest park located on Jeju Island (KTO)

Added to the Asian medicine category list is Lee Moon Won Medical Clinic, located in Seouls Cheongdam-dong. The clinic offers not only Asian medicine treatments, but also operates scalp immune enhancement programs and aroma massage therapy services.

Mayfield Hotel in western Seoul, Taekwondowon in Muju, North Jeolla Province, and Jeju 901, a brunch cafe and guest house with yoga programs in Jeju City, Jeju Island, are listed in the healing and meditation category.

By Kim Hae-yeon (hykim@heraldcorp.com)

Go here to see the original:
Seek health and well-being at wellness tourism destinations - The Korea Herald

United States Pain Management Therapeutics Market Forecast Report 2022-2028: Industry Trends, Outlooks, Impact of COVID-19, Company Analysis -…

DUBLIN--(BUSINESS WIRE)--The "United States Pain Management Therapeutics Market, Forecast 2022-2028, Industry Trends, Outlooks, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

U.S. Pain Management Therapeutics Market Size was valued at US$ 6.75 Billion in 2021 and will reach US$ 12.55 Billion in 2028

Patients with acute and chronic pain have faced a crisis in the United States for years due to severe problems accessing sufficient care, resulting in considerable physical, emotional, and societal expenses.

To treat pain caused by inflammation in reaction to tissue injury, chemical agents/pathogens (nociceptive pain), or nerve damage, a variety of pain management therapies are employed (neuropathic pain).

Most gadgets and medications work by attaching to protein targets on cell membranes and altering the body's biochemical processes. Nonetheless, prescription opioids, heroin, and synthetic opioids have been linked to an alarming increase in overdose mortality during the last two decades.

U.S. Pain Management Therapeutics Industry will grow with 9.3% CAGR from 2021-2028

In recent years, because of the geriatric population in the United States, there has been an increase in pain management therapeutics.

Furthermore, the rising preponderance of diseases such as cancer, diabetic neuropathy, osteoarthritis, and chronic arthritis and an increase in surgical procedures and healthcare spending are key factors driving the market for pain management therapeutics in the United States. Furthermore, rising healthcare awareness propels the global pain management medications market forward.

COVID-19 Outbreak Effect on Pain Management Therapeutics Industry in the United States:

Most industries, including the medical device industry, were affected by the COVID-19 pandemic. Patients who rely on exercise programs or physical therapy as a pain management regimen have been affected by nationwide lockdowns.

Furthermore, numerous elective surgeries and in-person patient visits have been halted or postponed, increasing the demand for at-home pain therapy. Lockdown measures adopted by governments in many nations also hampered manufacturing activities. Furthermore, the supply chain was interrupted, resulting in raw material shortages.

By Pain Type, United States Pain Management Therapeutics Market Is Classified into Acute Pain and Chronic Pain:

The United States Pain Management Therapeutics Industry is divided into two categories in our report: Acute Pain and Chronic Pain. Acute pain occurs suddenly, whereas chronic pain lasts for a long time.

Chronic pain is mainly caused by bone and joint aging, nerve damage, and injury. To treat or lessen the symptoms of these types of pain, a specific collection of medications is used. On the other hand, the pain process is complicated, and there is a range of medicines that provide relief by working on a variety of physiological mechanisms.

Pharmaceuticals Holds the Dominant Share In The Market:

Pharmaceuticals and devices are among the numerous forms of pain-relieving medications based on therapies, and each therapeutic operates in a slightly different way.

Furthermore, the effectiveness of a pain-relieving medicine for a particular type of pain and the risk of adverse effects in a specific person determine the medication's selection. Pharmaceuticals, according to our research, have the largest market share. Furthermore, with technological advancements, the gadgets segment is likely to rise.

Device Insights of Pain Management Therapeutics Industry in the United States:

The neurostimulation category controls the significant market. The rising occurrence of neurological illnesses can be blamed for dominance.

Furthermore, neurostimulators are essential in treating chronic pain, Parkinson's disease, epilepsy, movement disorders, and depression. In addition, the segment is expected to develop due to factors such as rising product demand, the launch of technologically sophisticated items, and the growing elderly population.

Aside from that, due to its broad applicability in pain management, surgical oncology, gynecology, cardiology & cardiac rhythm management, and cosmetology, radiofrequency ablation is predicted to increase at the quickest rate over the projection period. Radiofrequency ablation is more advantageous than open surgery in treating patients with numerous tumors, which drives up demand.

NSAIDs Segment Reports Foremost Market Share:

NSAIDs have the largest market share in the US pain management therapeutics industry. The substantial market share of NSAIDs is due to their availability as over-the-counter medications and inexpensive costs. Nonsteroidal anti-inflammatory medicines are also in high demand due to characteristics such as the convenience of use and fast pain alleviation (NSAIDs).

By Indication, Neuropathic Pain is projected to dominate the Indication Segment:

The somatosensory nerve system is damaged or afflicted, resulting in neuropathic pain. The majority of neuropathic pain is persistent. One instance of neuropathic pain is phantom limb syndrome.

When a leg or an arm is severed due to an injury or sickness, the brain continues to receive pain signals through the nerves used to carry impulses from the missing limb. Pain is caused by nerve misfiring. Because neuropathic pain is chronic, pain-relieving drugs are given frequently, resulting in a significant revenue share.

Key Companies Insights:

Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Boehringer Ingelheim are among the prominent industry participants covered in the analysis.

To increase their market position in the United States, significant corporations have attempted several strategic efforts, including technology innovation, partnerships, regional expansion, and mergers and acquisitions.

Companies Covered:

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. US Pain Management Therapeutics Market

6. Market Share - US Pain Management Therapeutics Market

6.1 By Therapeutics

6.2 By Devices

6.3 By Drug Class

6.4 By Indication

6.5 By Pain Type

7. Therapeutics - US Pain Management Therapeutics Market

7.1 Pharmaceuticals

7.2 Devices

8. Devices - US Pain Management Therapeutics Market

8.1 Electrical Stimulators

8.2 Radiofrequency Ablation

8.3 Analgesic Infusion Pumps

8.4 Neurostimulation

9. Drug Class - US Pain Management Therapeutics Market

9.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

9.2 Anesthetics

9.3 Anticonvulsants

9.4 Anti-Migraine Agents

9.5 Antidepressants

9.6 Opioids

9.7 Nonnarcotic Analgesics

10. Indication - US Pain Management Therapeutics Market

10.1 Arthritic Pain

10.2 Neuropathic Pain

10.3 Cancer Pain

10.4 Chronic Back Pain

10.5 Post-Operative Pain

10.6 Migraine

10.7 Fibromyalgia

10.8 Bone Fracture

10.9 Muscle Sprain/Strain

10.10 Acute Appendicitis

10.11 Others

11. Pain Type - US Pain Management Therapeutics Market

11.1 Chronic Pain

11.2 Acute Pain

12. Porter's Five Forces Analysis

12.1 Threat of New Entry

12.2 The Bargaining Power of Buyer

12.3 Threat of Substitution

12.4 The Bargaining Power of Supplier

12.5 Competitive Rivalry

13. Company Analysis

13.1 Overview

13.2 Recent Development

13.3 Financial Insights

For more information about this report visit https://www.researchandmarkets.com/r/it2f51

See the original post:
United States Pain Management Therapeutics Market Forecast Report 2022-2028: Industry Trends, Outlooks, Impact of COVID-19, Company Analysis -...

Should medical errors be criminalized? This Fort Worth medical school offers another way – KERA News

Vanderbilt nurse RaDonda Vaught was chatting with a mentee the day after Christmas in 2017 when she typed the first two letters of her patients prescription into the drug cabinet monitor: V-E.

She wanted Versed, a sedative to help the 75-year-old patient a woman hospitalized for a brain bleed relax before her final scan. Instead, she selected vecuronium, a drug that causes paralysis. Vecuronium was Vaughts top search result, and she didnt check the label before administering it.

Within the hour, her patient had no pulse. In fewer than 12, she had died. Later, the patients medical examiner report would identify her cause of death: acute vecuronium intoxication, an error for which Vaught would, just last month, be criminalized.

In the decades since patient safety surfaced as a research priority, no official count of accidental patient deaths exists, but some experts estimate the number in the U.S. could be in the hundreds of thousands each year. The system is not improving, said Lillee Gelinas, a nurse and course director for patient safety at the Texas College of Osteopathic Medicine. And you have to back up and say, Why?

Since 2019, before Vaughts conviction swept national headlines, Gelinas and her colleagues at the medical school have worked to answer that question. One solution, she said, is academic which is why, in 2020, the Texas College of Osteopathic Medicine became the only medical school in the world to require its students to take the internationally recognized Certified Professional in Patient Safety exam.

At the end of the day, we are committed to developing safe providers of the future, she said. Its our responsibility and accountability to our community.

An epidemic of preventable harm

The second chapter of the seminal report, To Err is Human: Building a Safer Health System begins somberly: Health care is not as safe as it should be.

The 1999 report, published by the organization now known as the National Academy of Medicine, estimated that as many as 98,000 hospitalized Americans die each year from medical errors. The insights galvanized the patient safety movement as we know it today, Gelinas said.

More recent studies expand those estimates. In 2016, an analysis from Johns Hopkins University School of Medicine suggested that number could be more than 250,000 people each year, making medical error the third leading cause of death in the U.S. before the pandemic.

The uncertainty comes, in part, from the continued lack of a nationwide reporting system, which the To Err is Human report recommended. By 2015, just over half of the states, including Texas, required hospitals but not necessarily clinics or outpatient providers to report preventable harm.

The bottom line: The amount of preventable harm and death is too many, Gelinas said. Her boss and the dean of the Texas College of Osteopathic Medicine, Dr. Frank Filipetto, calls it an epidemic.

Were carrying germs from patient to patient

Dr. Conner Reynolds was scribing for an emergency room physician in Waco when he noticed the physicians smartphone.

He would remove it from his pocket for every patient, calculating risk scores and checking treatment options first for the diarrhea patient, then the stroke patient, then the heart attack patient. Following protocol, the physician would wash his hands in between, but he didnt clean his phone.

Were carrying germs from patient to patient, Reynolds pointed out. He and the physician looked at each other. Is this OK? Is this something we need to consider?

The question led Reynolds, who was in college at the time, to pursue a research study on health care student cell phone use when he enrolled at the Texas College of Osteopathic Medicine. The results reflected his physicians behavior: Overall, health care students were likely to use their phones in the restroom and wash their hands afterward; however, they cleaned their phones less than once a week.

Reynolds, along with Gelinas, presented the research at the Institute for Healthcare Improvements national conference in late 2018. There, he learned about the Certified Professional in Patient Safety credential, an accolade that could only be earned by health professionals with three to five years of direct clinical experience under their belts.

The criteria excluded medical students, who typically start clinical rotations in year three and therefore wouldnt be eligible to sit for the exam until at least their second year in residency.

And we all sort of sat down and asked ourselves, Why in the world would we want to send providers out into health care, let them learn bad habits and then, five years later, teach them the right way to do things? Reynolds remembers.

He calls it a Eureka moment, and it aligned with the hiring of Filipetto, a staunch patient safety advocate, as dean of the medical school.

Tools to identify when theres problems in the system

The day after Filipetto had his tonsils removed as a 6-year-old, he felt something strange in the back of his throat. It was a piece of gauze, unintentionally left behind, and he started choking on it.

That was terrifying, he remembers. My parents didnt know what to do. Luckily, I was able to cough it up after a minute or two, but that was what we would call a near-miss.

Years later, when he was applying to become dean, patient safety was part of his platform. We know that people make mistakes. Theyre not intentional, he said. Its impossible to prevent human error, but how do we create a system whereby the system either catches that or where bad outcomes dont occur?

The patient safety component was part of a larger curriculum shift Filipetto had advocated: the inclusion of health systems science to a traditional spate of courses like anatomy and clinical skills. Health systems science takes a birds-eye view of health care delivery, requiring a critical look at how health professionals work together.

You want a (medical) student thats a systems thinker, that doesnt just think siloed You also want somebody that has an open mindset, said Dr. Janet Lieto, who directs the health systems science curriculum at the medical school.

After the Eureka moment, Lieto and Gelinas set to work creating a patient safety course for the schools medical students. Their first priority: collaborating with the Institute for Healthcare Improvement, an organization that provides educational resources for the Certified Professional in Patient Safety exam.

To prove that medical students could, indeed, pass the exam before three years of clinical experience, they received permission from the Certification Board to pilot a patient safety course with 10 students nine of whom passed the exam on the first try. The national average is 70%.

Texas College of Osteopathic Medicine

/

Once the Institute for Healthcare Improvement and the Certification Board gave the go-ahead, the college received the necessary approvals to incorporate patient safety into the schools curriculum. Less than two years after the Eureka moment, in July 2020, the Texas College of Osteopathic Medicine became the only medical school in the world that requires its students to take the patient safety certification exam before graduating.

The Institute for Healthcare Improvement tracks data on every person who has passed the exam, a spokesperson told the Fort Worth Report. She confirmed the Texas College of Osteopathic Medicines globally unique status.

On the institutes website, Texas list of certified professionals vastly overshadows that of other states. After nearly 500 medical students have taken the patient safety course, the schools pass rate is 98%.

The course itself spans just two weeks, about eight hours a day, during a medical students third year, Gelinas said. The cost to each student, which covers the training materials and the exam, is about $900. When they pass the exam, students can add C.P.P.S. to their white coats.

When Reynolds, who passed the exam in 2021, applied for residency programs, the initials came up again and again in his interviews. Now, as a resident at JPS Health Network, hes helping his colleagues develop safer systems to protect their patients.

The initials after the name isnt the most important thing, Lieto said. The most important thing is giving them those tools to identify when theres problems in the system.

We can eliminate preventable death

Charlene Murpheys head ached when she checked into the emergency room at Vanderbilt University Medical Center in Nashville, Tennessee. It was Christmas Eve 2017, and Murphey had been shopping earlier that day, according to a Centers for Medicare & Medicaid Services report.

The 75-year-old lived about 30 miles away, in a suburb called Gallatin, and had had her share of health troubles: Guillain-Barre syndrome, lupus and breast cancer, but her prognosis looked hopeful. A CT image revealed bleeding in her brain, but her condition improved, and by Dec. 26, she was almost ready to leave. Before her final scan, Murphey mentioned she was claustrophobic, and her physician prescribed Versed to calm her nerves.

Months after Murphey died from vecuronium intoxication, the Centers for Medicare & Medicaid paid Vanderbilt University Medical Center a surprise visit.

Inspectors found the hospitals policies lacked guidance about when and how to monitor patients after administering high-alert drugs like vecuronium. The report also determined the hospital lacked adequate safety measures to prevent providers from accidentally acquiring such medicines from the drug cabinet. Finally, the hospital had not reported the error to the Tennessee Department of Health, a requirement by state law.

So when people talk about safety, I worry that they just see that (Vaught) made this mistake, Lieto said. You have to ask why and when you come down to it, its usually a system error or a process error in addition to a human error. And thats the piece that people forget about.

Vaughts criminal conviction in late March undercuts a key component of patient safety, Gelinas said: Just culture, or an environment where people feel safe to discuss mistakes without fear of punishment. This one case, the criminalization of medical error, has really put a chilling effect on a lot of the progress that weve made, she said.

A patient safety course like the one at the Texas College of Osteopathic Medicine acknowledges that, while people make mistakes, good systems can prevent bad outcomes. Gelinas hopes more and more medical schools come to adopt a similar strategy; she and Lieto are scheduled to present their success at the Institute for Healthcare Improvements Patient Safety Congress in May.

So long as it involves humans, health care will never be free of errors, she said. But it can be free of preventable death.

Whats the problem?

Although no official count of accidental patient deaths exists, some experts estimate the number in the U.S. could be in the hundreds of thousands each year.

Whats a possible solution?

Since 2020, the Texas College of Osteopathic Medicine has required its medical students to take a patient safety course and the Certified Professional in Patient Safety exam before graduating. The requirement involves a collaboration between the school and the Institute for Healthcare Improvement.

Continued here:
Should medical errors be criminalized? This Fort Worth medical school offers another way - KERA News

FTC announces settlement with for-profit medical school alleged to have engaged in deceptive marketing – Consumer Finance Monitor

The FTC has announced a stipulated order of judgment in a lawsuit that it recently filed against Saint James School of Medicine, a for-profit medical school located in the Caribbean, together with its operator and financiers. The $1.2 million judgment will be used toward refunds and debt cancellation for students who financed their education within the past five years.

In its complaint, the FTC alleged that Saint James and its operators violated the FTC Act, the TSR, the Holder Rule, and the Credit Practices Rule. The FTC specifically alleged that Saint James lured consumers with false guarantees of student success, and made false or unsubstantiated representations regarding potential students likelihood of matching into residency programs upon graduation The FTC further alleged that the Defendants financing contracts contain language attempting to waive consumers rights under federal law and omit legally-mandated disclosures.

According to the FTC, Saint James misrepresented the Medical License Exam Pass Rate, claiming 96.77% FIRST TIME USMLE STEP 1 PASS RATE. The FTC alleged that since 2017, only 35% of Saint James students who have completed the necessary coursework passed the USMLE Step 1 exam. The FTC also alleged that Saint James misrepresented the residency match rate, the percentage of medical school seniors who are accepted for residencies, stating Saint James falsely advertised their residency match rate was 83% (since 2018, the average match rate for Saint James students has been 63%).

With regard to Saint James financers, the FTC alleged that the financing contracts did not include federally required language under the Holder Rule and failed to provide the cosigners with the required Notice to Cosigner.

The proposed judgment also requires Saint James and its co-defendants to request tradeline deletion from consumer reporting agencies for Saint James students who financed their education through the corporate defendants within the past five years. The judgment prohibits Saint James and its financers from continuing the alleged misrepresentations and engaging in further violations of law. Additionally, the judgment permanently restrains and enjoins the defendants from extending credit to a consumer unless the Notice to Cosigner Disclosure [] has been given to the cosigner prior to becoming obligated.

In response to the FTCs announcement of the proposed judgment, the director of Saint James issued a statement explaining the schools decision to enter into a settlement despite its strong disagreement with the FTCs approach. The director stated:

[W]e did not want a lengthy legal process to distract from our mission of providing a quality medical education at an affordable cost. However, we have added additional language and clarifications any time the USMLE pass rate and placement rates are mentioned. We are committed to being an industry leader for transparency and accountability and hope that our efforts will lead to lasting change throughout the for-profit education industry.

See the rest here:
FTC announces settlement with for-profit medical school alleged to have engaged in deceptive marketing - Consumer Finance Monitor

Exceptionally driven: A Ph.D. and D.O. in hand, Rahil Kheirkhah eyes a future in surgery, research – Rowan Today

Rahil Kheirkhah is on a mission.

Earning her medical degree from Rowan Universitys School of Osteopathic Medicine (RowanSOM) on May 9, she will head to a five-year general surgery residency program with the ChristianaCare health system in Newark, Delaware.

She is bringing extraordinary credentials to her patients: a doctor of osteopathic medicine degree as well as a doctoral degree in cell and molecular biology from Rowans Graduate School of Biomedical Sciences, which she earned in 2020. Kheirkhah is only the second female DO/PhD in the schools history.

The Linwood resident has always wanted to be a doctor.

I dont think I ever considered doing anything else. I knew I wanted to help people, and being a doctor was the only thing I ever thought about, she said. My family taught me a very central tenet of my life, which is you want to live your life serving others and you want to live your life giving back and always listening to the people around you.

Her parents embodied this message as they fought to reestablish themselves in a new country. Her father was a family physician and her mother a science teacher in Iran. But after they arrived in the United States when Kheirkhah was 11, they worked diligently to build new careersher father as a nurse and her mother as a real estate agent.

New opportunities

After she began medical school, Kheirkhah discovered additional ways to help patients as well as her classmates.

She founded Humans of RowanSOM, a platform that showcased each person at the school with photos and short quotations.

Moved by a talk given by Dr. Robert Nagele, professor of medicine at RowanSOM, she was selected for a summer medical research fellowship after her first year.

When I worked with them in the lab, I loved what they were doing, she said. It was very cutting edge and innovative, like nothing Id ever heard about before.

This led her to earn her doctorate within three years, receiving the Deans Award for Excellence in Research in 2018. She worked on research to develop a blood test to diagnose early-stage Alzheimers disease, which would detect the disease before patients begin to show symptoms, enabling earlier treatment.

It was probably the best decision Ive made in my seven years at Rowan, she said. Working with them gave me a chance to not only grow professionally, but also grow personally.

In Nageles program, she learned to perform and analyze research and refine her abilities to take a critical approach to problem-solving. She also assumed leadership roles on projects.

It taught me to feel comfortable about questioning the material that Im taught, looking for answers and where the answers are coming from, and approaching situations in a very scientific way.

It made me more confident that when I am practicing medicine, Ill be learning skills and reading information that is scientifically sound and making decisions that are objectively beneficial for my patients, she said.

Nageles guidance was invaluable, according to Kheirkhah.

He taught me not to shrink away from a challenge and, more importantly, to become comfortable making big decisions and standing behind them, she said. He was an incredible mentor to have, and I feel very grateful to have been able to work with him.

Handling the pressure

After earning her doctorate, Kheirkhah returned to her medical studies. She plans to continue performing research in a clinical setting, and she was drawn by the teamwork and intensity of surgery.

Theres an immediacy and urgency that demands that you be completely present in that moment, Kheirkhah said.

When youre in the operating room, it can be unpredictable and intense, and that resonated with the intense unpredictability I had been feeling growing up as an immigrant for the last 17 years, she continued.

I feel like the person who I am now was formed under a very pressurized environment, which is very similar to how you are when youre in an operating room.

Based on her experience as an immigrant, she also believes she will be able to empathize and connect with patients who feel vulnerable.

Those individual one-on-one connections are really where you can make your mark, showing who you are and what your signature is as a doctor, she said.

Marcin Jankowski, DO, MBA, FACOS, associate clinical professor at RowanSOM and trauma surgeon at ChristianaCare, has observed Kheirkhahs strong drive to help others.

Rahil is unique in that not only has she found her passion for the field of surgery, she has also found her purpose by using that passion to serve others. To a mentor, there is nothing more rewarding than to witness your mentee go through such a profound transformation and ultimate realization. I am confident that she will make an excellent and caring surgeon.

Savoring every moment

Kheirkhah is grateful for the people she met at Rowan who supported and listened to her.

Your mentors are such a significant part of where you end up in life, she said. They nudge you in the right direction, and with the right people standing behind you, you can go so far.

She eagerly awaits the next step in her career.

Im going to the hospital of my dreams and Im doing the residency of my dreams, Kheirkhah said.

Im looking forward to being the best I can be and to take this opportunity in as fully as possible as time flies bysavoring every single moment. I just want to try to be as present as possible.

Go here to see the original:
Exceptionally driven: A Ph.D. and D.O. in hand, Rahil Kheirkhah eyes a future in surgery, research - Rowan Today

UMass Chan Medical School offering $25 gift cards for participation in COVID at-home test study – MassLive.com

People taking at-home COVID-19 tests now have the chance to get paid for it thanks to a University of Massachusetts Chan Medical School study.

The study will look at the performance of new at-home tests, according to Sarah Willey, a spokesperson for the school.

Researchers are hoping to enroll 1,300 participants, to obtain a minimum number of results that test positive for disease, she said.

Participants will have to download the MyDataHelps app, answer questions and perform three types of COVID-19 tests at home over one to two days, according to Willey.

The tests will be provided at no costs and once participants use them, they will have to mail their sample to a lab for PCR testing.

Once all the steps are completed the participants will be provided with a standard $25 gift card, Willey said.

Anyone in the U.S. over the age of two can participate, except those in Arizona due to lab limitations.

Participants will receive their results two to five days after shipping, according to Willey.

The study is part of the RADx digital Independent Test Assessment Program (ITAP), which helps researchers confirm the performance of new rapid antigen testing, as they seek to bring more high-quality tests to market, Willey said.

UMass Chan researchers have also evaluated the impact of the SayYes! COVID Test program in Michigan where 500,000 free at-home rapid antigen tests were distributed to residents of Ann Arbor and Ypsilanti in the summer of 2021.

According to the study, which has not been peer-reviewed, during the delta variant surge two months after the program, infection rates were significantly lower in the cities that received the at-home tests.

Its clear that at-home rapid antigen tests are useful, and they have tremendous value at an individual level in terms of how people decide to live their lives in the pandemic, but also provide invaluable information to experts at a population health level, Dr. Apurv Soni, assistant professor of medicine at UMass Chan and principal investigator on the study.

Soni is also the principal investigator for this latest at-home test study.

Anyone interested in participating can download the MyDataHelps app to sign up.

Related Content:

See original here:
UMass Chan Medical School offering $25 gift cards for participation in COVID at-home test study - MassLive.com

Perelman School of Medicine 2022 Teaching Awards | University of Pennsylvania Almanac – Almanac

Perelman School of Medicine 2022 Teaching Awards Deans Award for Excellence in Clinical Teaching (at an Affiliated Hospital)

The Deans Award for Excellence in Clinical Teaching was established in 1989 to recognize clinical teaching excellence and commitment to medical education by outstanding faculty members from affiliated hospitals. One or more Deans Awards are given annually, the recipients being selected on the advice of a committee composed of faculty and students.

Judd Flesch is an assistant professor of clinical medicine in the department of medicines division of pulmonary, allergy, and critical care. He graduated from the Perelman School of Medicine in 2006 and subsequently completed his internal medicine residency, chief residency, and pulmonary/critical care fellowship at the Hospital of the University of Pennsylvania. During his fellowship, he also served as the Mayock Chief Fellow. He joined Penns faculty in January 2014 and has served as an associate program director of the Internal Medicine Residency Program and site director at Penn Presbyterian Medical Center (PPMC) for the past eight years. In addition to overseeing clinical rotations at PPMC, Dr. Flesch also oversees the mentorship program for residents. He is passionate about clinical teaching, working with residents, fellows, and medical students in both inpatient and outpatient settings. In addition to his educational roles, Dr. Flesch is active in clinical operations leadership at PPMC, serves on the department of medicine Professionalism Committee, and is the co-director of the Penn Medicine Program for LGBTQ Health.

Temitayo Ogunleye is an associate professor of clinical dermatology and the associate director of diversity, equity, and inclusion in the department of dermatology. She received her medical degree from the Perelman School of Medicine, completed her residency training in dermatology at the University of Michigan, and trained at the University of Pennsylvania as a clinician educator fellow to further her interests in medical education and develop her current niches of skin color and hair disorders. Dr. Ogunleye received a masters degree in healthcare innovation from Penn in 2021 and was appointed as medical director of the dermatology clinic at the Perelman Center for Advanced Medicine in January 2022. She plays an active role in medical education, interacting with both medical students and residents in her clinics and on inpatient consultations at Penn Presbyterian Medical Center. She is a member of her departments Clinical Competency Committee and serves as a GME Ombudsperson. She is also a faculty leader of the Faculty Forums committee of the Alliance of Minority Physicians, a resident-led organization comprised of residents, fellows, and attending physicians who are underrepresented in medicine and committed to creating a diverse workforce. A former trainee commented, (she) is simply the best. She is kind, courteous, charismatic. She is a great teacher andI love working with her.

Carla R. Scanzello is an associate professor of medicine in the division of rheumatology at the Perelman School of Medicine, and section chief of rheumatology at the Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) in Philadelphia. Dr. Scanzello received her medical and graduate degrees from Temple University School of Medicine in Philadelphia, completed her residency training at New York-Presbyterian/Weill Cornell Medical Center, and her rheumatology fellowship at the Hospital for Special Surgery in New York. She joined Penn and the CMCVAMC in 2013, where she established a laboratory focused on osteoarthritis therapeutic development within the Translational Musculoskeletal Research Center, which she now co-directs. In addition to her research pursuits, she is dedicated to education of clinical trainees. She regularly supervises rheumatology fellows in their weekly VA clinics and participates as a faculty member in PSOMs Cell & Tissue Biology and Mechanisms of Disease and Therapeutic Interventions courses. She teaches medical students and trainees from multiple specialties and primary care rotating through the rheumatology clinics at the CMCVAMC. This includes bedside teaching within the CMCVAMC Multi-Disciplinary Osteoarthritis Clinic, which she co-established. In partnership with colleagues in endocrinology and radiology, she co-organizes quarterly conferences in metabolic bone disorders for trainees at the CMCVAMC. In all these settings, she encourages trainees to set educational goals for themselves to foster a lifetime of self-directed learning and to collaboratively engage colleagues from other specialties to optimize inter-disciplinary care for patients. As former trainees have commented, Dr. Scanzello is an outstanding teacher. She regularly helps fellows develop learning goals and then revisits these to check in on progress. I appreciate that she takes into account my learning goals and actively incorporates these into her teaching styleShe is a great role model as a rheumatologist.

Nicole Washington is an assistant professor of clinical pediatrics within the department of pediatrics at the Perelman School of Medicine and an attending physician with the division of general pediatrics at the Childrens Hospital of Philadelphia (CHOP). Dr. Washington received her BA in Spanish and her medical doctorate from the University of Virginia. She completed her pediatric residency training at CHOP. After completing her residency, she served as a pediatric chief resident for the hospital and the pediatric residency program. Dr. Washington remains active in the pediatric residency program, serving as one of the associate program directors and an integral member of the Intern Selection Committee; she also is currently the chair of the American Board of Pediatrics Education and Training Committee. Dr. Washington is one of the faculty mentors of the Alliance of Minority Physicians, a resident-led organization at CHOP comprised of residents, fellows, and attending physicians who are underrepresented in medicine and committed to creating a diverse workforce. Dr. Washington has mentored countless residents, medical students, and undergraduate students with a strong dedication to ensuring their personal and professional growth. Dr. Washington is also committed to her own professional growth and improvement, and is currently enrolled in the College of Liberal & Professional Studies Master in Organizational Dynamics Program. She plans to share this new knowledge and growing expertise with her trainees to further their leadership development.

This award was established by the department of anesthesia in 1984. As a pioneer in the specialty of anesthesia and chair of the department from 1943 to 1972, Dr. Dripps was instrumental in the training of more than 300 residents and fellows, many of whom went on to chair other departments. This award is to recognize excellence as an educator of residents and fellows in clinical care, research, teaching, or administration.

David Aizenberg is an associate professor of clinical medicine in the division of general internal medicine. He came to Penn in 2007 as an intern and stayed on to complete his residency and a chief resident year. He then joined the faculty and continued to have an active role within the internal medicine residency. Dr. Aizenberg enjoys optimizing learning environments and has led several educational innovations, including transitioning the program into a block scheduling system and designing and implementing a theme-based ambulatory curriculum. In 2018, Dr. Aizenberg left Penn to lead the Drexel/Hahnemann University Hospital internal medicine residency as its program director. During the unexpected closure of Hahnemann, Dr. Aizenberg advocated on behalf of all the residents and fellows impacted by this crisis and helped them to find receiving programs. Dr. Aizenberg returned to Penn in 2020 and joined the GME leadership team as director of assessment and professional development. In this role, he helps programs improve their assessment systems and coaches struggling housestaff. Dr. Aizenberg continues to be clinically active in outpatient primary care and the inpatient wards at PPMC.

Created in 1987 by the Blockley Section of the Philadelphia College of Physicians, this award is given annually to a member of the faculty at an affiliated hospital for excellence in teaching modern clinical medicine at the bedside in the tradition of William Osler and others who taught at Philadelphia General Hospital.

Sean Harbison is a native Philadelphian, having spent almost his entire education and professional career within blocks of Broad Street. After earning his BA in biology from LaSalle College, Dr. Harbison attended Temple University School of Medicine and completed general surgery training at the Graduate Hospital and at Memorial Sloan Kettering Cancer Center in New York. He has served as a faculty attending surgeon and professor of surgery at Graduate Hospital, Temple University Hospital and, most recently, in the department of surgery at the Perelman School of Medicine, where he focuses on educational roles at each institution. For the past 8 years he has served as an associate clerkship and sub-internship director in the department of surgery, and he recently earned a masters degree in medical education from Penn. He has had his teaching prowess recognized by multiple teaching awards, including induction into AOA Medical Honor Society (2005), three Penn Pearl Awards (1995, 2017, 2021), and the Deans Award for Clinical Teaching (1997). A former student stated, I hope to emulate your style with patients and students when Im a physician: Thank you for making me feel like a valued team-member and [for] an inspired learning experience.

This award was established in 1981 as a memorial to Leonard Berwick by his family and the department of pathology. It recognizes a member of the medical faculty who in his or her teaching effectively fuses basic science and clinical medicine. It is intended that this award recognize persons who are outstanding teachers, particularly among younger faculty.

Katharine Bar is an assistant professor of medicine in the division of infectious diseases and a physician-scientist studying novel approaches to HIV prevention and cure. Her translational research program fuses a virology laboratory studying the basic mechanisms of viral pathogenesis with clinical trials of HIV and SARS-CoV-2 interventions. Dr. Bar is an engaged teacher in both her clinical and research roles at Penn and through her leadership in national scientific organizations. She precepts medical trainees and leads multiple small group sessions for medical students, internal medicine residents, and infectious disease fellows. She is also an active teacher of cell and molecular biology graduate students, for whom she co-directs a journal club format class centered on HIV. Through her laboratory, she serves as a formal mentor for multiple students and an informal mentor to many additional trainees, in particular women pursuing basic and translational research careers. Outside of Penn, she is known as a dynamic speaker who communicates complex concepts in an engaging manner. A physician-scientist trainee mentored by Dr. Bar wrote, Dr. Bar has consistently mentored me through graduate and clinical phases of my development as a physician-scientist, always reminding me of the duality of my training. I have witnessed Dr. Bars tailored mentorship of numerous friends who are graduate students, medical trainees, and budding physician-scientists. She assesses a mentees needs and meets them at their level. Her advice is honest, thoughtful, and based on her wealth of experience as a successful physician-scientist.

This award was established in 2000 by the Penn/VA Center for Studies of Addiction and the department of psychiatry. Scott Mackler is known for his excellence in teaching medical students, residents, post-doctoral fellows, nurses, and other Penn faculty in many different departments in the area of substance abuse.

Subhajit Chakravorty is an assistant professor of psychiatry at the Perelman School of Medicine and a staff physician at the affiliated Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC). He completed his medical school training at the University College of Medical Sciences, Delhi, India. He trained in psychiatry at the University of Pittsburgh and completed his sleep medicine training and a master of science in translational research at the University of Pennsylvania. In addition, he completed his addiction research and clinical care fellowship at the affiliated CMCVAMC. He is certified in psychiatry, sleep medicine, and addiction medicine. He attends to patients in sleep medicine at the Hospital of the University of Pennsylvania and addiction psychiatry at CMCVAMC.

His program of research focuses on developing personalized treatment interventions for insomnia comorbid with alcohol use disorder and their underlying mechanisms for change. Additionally, he is interested in understanding how alcohol use interfaces with sleep-related disorders.

The Deans Award for Excellence in Basic Science Teaching was established in 1988 to recognize teaching excellence and commitment to medical student teaching in the basic sciences. One or more Deans Awards are given annually, the recipients being selected on the advice of a committee comprised of faculty and students.

Rahul Kohli is an associate professor of medicine in the division of infectious disease, with a secondary appointment in the department of biochemistry and biophysics. Dr. Kohli obtained his MD and PhD from Harvard Medical School, after which he completed his internal medicine residency at Penn and his post-doctoral fellowship and clinical infectious disease training at Johns Hopkins University. The chief objective of his research group has been to probe DNA modifying enzymes and using approaches rooted in enzymology and chemical biology. The enzymes targeted by his groups studies catalyze the purposeful modification of the genome and are central to host-pathogen interactions or to epigenetics. Dr. Kohlis work has been recognized through support from the Burroughs Wellcome Fund, the Doris Duke Foundation, the Rita Allen Foundation and an NIH Directors New Innovator Award, among others. He has been elected to the American Society for Clinical Investigators (ASCI) and has received the American Chemical Society (ACS) Pfizer Award in Enzyme Chemistry. At Penn, Dr. Kohli is dedicated to the mission of training the next generation of physician-scientists grounded in basic science. Since 2014, he has served as an associate program director of the Penn MD/PhD program. His roles in the program include supporting combined degree students in the Biochemistry and Molecular Biophysics Graduate Group and being the course director for Topics in Molecular Medicine, a course aimed at introducing all first-year combined degree students to cutting edge basic science work with medical implications.

This award was established in 1997 to recognize outstanding teaching by allied health professionals (e.g.; nurses, physicians assistants, emergency medical technicians). The recipient is selected on the advice of a committee composed of faculty and students.

Michelle Jackson has nearly 15 years of experience as a clinician working in the field of individual, couple, and family therapy. She holds a BA in womens studies and philosophy from Temple University and an MSS in clinical social work from the Bryn Mawr College Graduate School of Social Work and Social Research. Currently, Ms. Jackson is an attending faculty member in the Psychiatry Residency Assessment Clinic for third-year residents at Penn. She adds family and systems perspectives to the overall discussion of patients presenting for care and also ensures that residents consider race, gender, sexual orientation, social class, and cultural background for all of their new and on-going patients. Ms. Jackson was on the clinical faculty of the Center for Couples and Adult Families in the department of psychiatry at Penn Medicine until 2019. In that position, she collaborated with the clinical director and other colleagues to provide therapy for a wide variety of family life cycle transitions, adjustment and mood disorders, and relationship concerns. In addition to her work at Penn, Ms. Jackson has been a valued instructor for undergraduate, graduate, and post-graduate students since 2014. She has taught in the department of psychology at Philadelphia University (now part of Thomas Jefferson University), in the Rutgers University School of Social Work, in the Couple and Family Therapy program at Thomas Jefferson University, and in the post-graduate certificate program at Council for Relationships. Known for her enthusiasm and dynamism in the classroom, Ms. Jackson is sought after as a student advisor, professional mentor, and clinical supervisor.

This award was established in 2015 to recognize clinical teaching excellence and commitment to medical education by outstanding housestaff. One award is given annually. The recipient is selected on the advice of a committee composed of faculty and students.

Stphane Vie Guerrier is a senior internal medicine resident at the University of Pennsylvania. She graduated from the Perelman School of Medicine in 2019. After she completes her residency in June of 2022, she will join Penns department of endocrinology as a fellow. She enjoys working alongside Penns hardworking and inquisitive medical students, who teach her unexpected lessons every day.

The Michael P. Nusbaum Graduate Student Mentoring Award was established in 2017 to honor Mikey Nusbaum as he stepped down from his role as Associate Dean for Graduate Education and director of Biomedical Graduate Studies.

Christopher Hunter is the Mindy Halikman Heyer Distinguished Professor of Pathobiology in Penns School of Veterinary Medicine. Dr. Hunter has been a mentor far beyond the borders of his own laboratory, through the T32 grant he leads, the courses he directs, and the regular connection with students across several graduate groups. Dr. Hunters thoughtful advice has guided several generations of biomedical graduate studies (BGS) students through their PhD education and beyond. His dedication to mentoring students and guiding them in reaching their scholarly potential exemplifies the type of scientist and mentor that Mikey Nusbaum represents.

The Jane M. Glick Graduate Student Teaching Award was established in 2009 by the Glick family in remembrance of Jane Glick and her dedication to the Biomedical Graduate Studies (BGS) programs.

Dan Beiting is an assistant professor of pathobiology in Penns School of Veterinary Medicine. Dr. Beitings creation of a new teaching model within Biomedical Graduate Studies through the development of the CAMB 714 DIY Transcriptomics course and his innovative approach to deliver biostatistics training with the BIOM 610 course will have a lasting impact on quantitative training for BGS students for years to come. His dedication to these efforts exemplifies the type of scientist/educator that Jane represented.

See the rest here:
Perelman School of Medicine 2022 Teaching Awards | University of Pennsylvania Almanac - Almanac

New nonprofit medical system in the works for NWA – Axios

An aerial view of Washington Regional Medical Center in Fayetteville. Photo courtesy of Washington Regional Medical System

The Alice L. Walton Foundation and Washington Regional Medical System will create a new nonprofit medical system focused on training future doctors, the two organizations announced Monday.

Why it matters: NWA residents are leaving the area for specialty health care because the population is increasing faster than the area can get doctors, such as cardiologists, oncologists and neurologists.

Context: This was born out of the partnership announced last summer between the Alice L. Walton Foundation and Cleveland Clinic to assess specialty health care in NWA.

The big picture: Washington Regional wants to become a regional academic health system focused on training doctors beyond general medicine, president and CEO Larry Shackelford tells Axios.

Between the lines: A lot of the specifics are TBD. It's too early to say for sure whether this means new construction, such as a hospital or clinics, Shackelford says.

What's next: The foundation and Washington Regional will develop operational plans by the end of this year.

Support local journalism by becoming a member.

Learn more

No stories could be found

Get a free daily digest of the most important news in your backyard with Axios NW Arkansas.

Support local journalism by becoming a member.

Learn more

Follow this link:
New nonprofit medical system in the works for NWA - Axios